17-11-6　ⓔ文献

  1. Moake JL: Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med, 2002; 126: 1430–1433.

  2. Amorosi EL, Ultmann JE: Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine, 1966; 45: 139–159.

  3. Chiasakul T, Cuker A: Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology Am Soc Hematol Educ Program, 2018; 2018: 530–538.

  4. 松本雅則，藤村吉博，他：血栓性血小板減少性紫斑病 (TTP) 診療ガイド2017．臨床血液，2017; 58: 271–281.

  5. Kremer Hovinga JA, George JN: Hereditary thrombotic thrombocytopenic purpura. N Engl J Med, 2019; 381: 1653–1662.

  6. Terrell DR, Williams LA, et al: The incidence of thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost, 2005; 3: 1432–1436.

  7. Mariotte E, Azoulay E, et al: Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross–sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol, 2016; 3: e237–245.

  8. Matsumoto M, Bennett CL, et al: Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One, 2012; 7: e33029.

  9. Asada Y, Sumiyoshi A, et al: Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res, 1985; 38: 469–479.

  10. Sadler JE: Pathophysiology of thrombotic thrombocytopenic purpura. Blood, 2017; 130: 1181–1188.

  11. Scully M, Cataland S, et al: Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost, 2017; 15: 312–322.

  12. Rock GA, Shumak KH, et al: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med, 1991; 325: 393–397.

  13. Alwan F, Vendramin C, et al: Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune–mediated thrombotic thrombocytopenic purpura. Blood, 2017; 130: 466–471.

  14. Joly BS, Coppo P, et al: Thrombotic thrombocytopenic purpura. Blood, 2017; 129: 2836–2846.

  15. Fujimura Y, Matsumoto M, et al: Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost, 2011; 9 Suppl 1: 283–301.

  16. Lim W, Vesely SK, et al: The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood, 2015; 125: 1526–1531.

  17. Scully M, Hunt BJ, et al: Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol, 2012; 158: 323–335.

  18. Yoshii Y, Fujimura Y, et al: Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30–day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions. Transfusion, 2017; 57: 2045–2053.